SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--VistaGen Therapeutics, Inc., a platform-enabled biopharmaceutical company applying embryonic stem cell technologies to discover, develop and commercialize small molecule drugs and protein therapeutics for diabetes and neurological disorders, announced today that it has been awarded $1.2 million in funding from the National Institutes of Health (NIH) to support final preparation and filing of the Company’s AV-101 Investigational New Drug application with the Food and Drug Administration in early 2008.
